| Gene Symbol | CD59 |
|---|---|
| Full Name | CD59 molecule (complement regulatory protein) |
| Chromosomal Location | 11p13 |
| NCBI Gene ID | 969 |
| OMIM | 107271 |
| Ensembl ID | ENSG00000085059 |
| UniProt ID | P13946 |
| Associated Diseases | Multiple Sclerosis, Stroke, Alzheimer's Disease, Paroxysmal Nocturnal Hemoglobinuria |
| Expression | All nucleated cells, neurons, glia, immune cells |
CD59 encodes a GPI-anchored cell surface glycoprotein that serves as a key complement regulatory protein. CD59 (also known as protectin or MAC-inhibitory protein) inhibits the formation of the membrane attack complex (MAC) by binding to C8 and C9 components during complement activation, preventing their polymerization into the lytic pore[1]. This protection is critical for cells that are continuously exposed to complement activation, particularly in the central nervous system where complement proteins can be locally synthesized.
CD59 is widely expressed on all nucleated cells, including neurons, astrocytes, oligodendrocytes, and microglia in the brain. Loss or dysfunction of CD59 contributes to complement-mediated cell death in multiple sclerosis, stroke, and Alzheimer's disease[2].
The membrane attack complex (MAC, C5b-9) forms when complement cascade activation generates C5b, C6, C7, C8, and C9 components that assemble into a pore in target cell membranes. CD59 prevents MAC formation by binding to C8 and C9 and blocking their incorporation into the growing pore[3]. This inhibition occurs at the cell surface and requires the GPI anchor for proper membrane localization.
Beyond complement regulation, CD59 participates in synaptic plasticity and function through mechanisms independent of complement inhibition. It interacts with the CD2-like receptor on lymphocytes and may influence synaptic pruning by microglia.
CD59 is attached to the outer leaflet of the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor, which localizes it to lipid rafts. This localization positions CD59 strategically near other complement regulators and signaling molecules in membrane microdomains.
Complement-mediated demyelination is a major pathogenic mechanism in multiple sclerosis. CD59 expression is reduced on oligodendrocytes and myelin in MS lesions, making these cells more vulnerable to complement attack[3:1]. The balance between complement activation and CD59 protection influences the extent of demyelination and axonal loss. Therapeutic approaches aiming to enhance CD59 expression on oligodendrocytes are under investigation.
Complement activation worsens neuronal damage following cerebral ischemia. CD59 protects neurons and glia from complement-mediated death during the inflammatory phase of ischemic injury[4]. Ischemia/reperfusion downregulates CD59 expression on vulnerable cells, amplifying complement-dependent damage. Complement inhibition or CD59 upregulation represents a neuroprotective strategy for acute stroke.
The complement system is activated in Alzheimer's disease brains, and MAC deposition has been observed in AD tissue[5]. CD59 may protect neurons from complement-mediated toxicity triggered by amyloid-beta and other pathological stimuli. Loss of CD59-mediated protection could contribute to synaptic loss and neuronal death in AD.
CD59 deficiency on blood cells (due to PIG-A gene mutations) causes complement-mediated hemolysis. While not a neurodegenerative condition, PNH demonstrates the critical role of CD59 in protecting cells from MAC-mediated lysis.
CD59 is expressed on:
Expression can be modulated by inflammatory cytokines (IFN-γ, TNF-α) and oxidative stress.
Ricardo SD, et al. Complement in neurological disease. Nat Rev Neurol. 2020. ↩︎
Wang J, et al. CD59 in neurodegeneration. Mol Neurobiol. 2019. ↩︎
Nichols EM, et al. Complement and complement regulatory proteins in multiple sclerosis. Front Immunol. 2021. ↩︎ ↩︎
Kim GH, et al. Complement C5a and CD59 in cerebral ischemia. J Neuroinflammation. 2021. ↩︎
Madhumangal J, et al. Complement system in Alzheimer's disease. Adv Clin Chem. 2022. ↩︎